{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where agency_id = \"EPA\", docket_id = \"EPA-HQ-OAR-2002-0095\" and posted_year = 2022 sorted by posted_date descending", "rows": [["EPA-HQ-OAR-2002-0095-0243", "EPA", "EPA-HQ-OAR-2002-0095", "Protection of Stratospheric Ozone: Allocation of Essential Use Allowances for Calendar Year 2000: Allocations for Metered-Dose Inhalers and the Space Shuttle and Titan Rockets [A-93-39-VII-A-3]", "Rule", "Final Rule", "2022-10-06T04:00:00Z", 2022, 10, "2022-10-06T04:00:00Z", "2000-03-28T04:59:59Z", "2022-10-06T18:47:51Z", "00-4520", 0, 0, "0900006483d7e781"], ["EPA-HQ-OAR-2002-0095-0242", "EPA", "EPA-HQ-OAR-2002-0095", "Protection of Stratospheric Ozone: Allocation of Essential Use Allowances for Calendar Year 2000: Allocations for Metered-Dose Inhalers and the Space Shuttle and Titan Rockets [A-93-39-VII-A-2]", "Rule", "Interim Final Rule", "2022-10-06T04:00:00Z", 2022, 10, "2022-10-06T04:00:00Z", "2000-02-08T04:59:59Z", "2022-10-06T18:39:59Z", "00-273", 0, 0, "0900006483d7e780"], ["EPA-HQ-OAR-2002-0095-0241", "EPA", "EPA-HQ-OAR-2002-0095", "Protection of Stratospheric Ozone: Allocation of 2000 Essential Use Allowances [A-93-39-VII-A-1]", "Proposed Rule", "Notice of Proposed Rulemaking (NPRM)", "2022-10-06T04:00:00Z", 2022, 10, "2022-10-06T04:00:00Z", "1999-12-03T04:59:59Z", "2022-10-06T18:32:18Z", "99-28506", 0, 0, "0900006483d7e77f"], ["EPA-HQ-OAR-2002-0095-0216", "EPA", "EPA-HQ-OAR-2002-0095", "Letter from Terence Young, Western Farmers Electric Cooperative (WFEC), Anadarko, OK. [A-93-39-XI-H-7]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:42:07Z", null, 0, 0, "0900006483d7e6e6"], ["EPA-HQ-OAR-2002-0095-0211", "EPA", "EPA-HQ-OAR-2002-0095", "Data Table: Annex I - Essential Use Nominations For 2002-2004 Authorized by the Thirteenth Meeting of the Parties (in metric tonnes). [A-93-39-XII-A-3]", "Supporting & Related Material", "Data", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:41:10Z", null, 0, 0, "0900006483d7e6ec"], ["EPA-HQ-OAR-2002-0095-0227", "EPA", "EPA-HQ-OAR-2002-0095", "International Pharmaceutical Aerosol Consortium (IPAC), Washington, DC. Request for Nomination of the MDI as an Essential Use. [A-93-39-II-A-4]", "Supporting & Related Material", "Publication - Copyrighted Materials", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:45:22Z", null, 0, 0, "0900006483d7e6bc"], ["EPA-HQ-OAR-2002-0095-0221", "EPA", "EPA-HQ-OAR-2002-0095", "J.H. McCord, Jr., Lab Manager, Davis & Floyd, Incorporated [A-93-39-XI-H-2]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:44:01Z", null, 0, 0, "0900006483d7e6e1"], ["EPA-HQ-OAR-2002-0095-0214", "EPA", "EPA-HQ-OAR-2002-0095", "Daniel M. Panek, Director, JLI Environmental Laboratories, Auburn, NY. [A-93-39-XI-H-9]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:41:56Z", null, 0, 0, "0900006483d7e6e8"], ["EPA-HQ-OAR-2002-0095-0208", "EPA", "EPA-HQ-OAR-2002-0095", "Letter from E. Allera and T. Halpern of Buchanan Ingersoll to S. Monroe of EPA re: Imminent Change in name of Sidmak Laboratories [A-93-39-XII-A-6]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:40:28Z", null, 0, 0, "0900006483d7e6f0"], ["EPA-HQ-OAR-2002-0095-0235", "EPA", "EPA-HQ-OAR-2002-0095", "40 CFR Part 82 Protection of Stratospheric Ozone: Allocation of 2000\nEssential Use Allowences; Notice of Proposed Rulemaking (64 FR 59141) [A-93-39-X-A-1]", "Supporting & Related Material", "Publication - Previous/Related FR Notice", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:46:03Z", null, 0, 0, "0900006483d7e6db"], ["EPA-HQ-OAR-2002-0095-0238", "EPA", "EPA-HQ-OAR-2002-0095", "Dr. B.A. Schwetz, Acting Principal Deputy Commissioner, U.S. Food and Drug Administration (FDA) to P. Stolpman, Director, Office of Atmospheric Programs (OAP), Office of Air & Radiation (OAR), USEPA. [A-93-39-XI-A-2]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:46:48Z", null, 0, 0, "0900006483d7e6dd"], ["EPA-HQ-OAR-2002-0095-0230", "EPA", "EPA-HQ-OAR-2002-0095", "K. H. Mody, Director of Operations, Medisol Laboratories, Inc., East Hanover, NJ. [A-93-39-II-A-6]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:45:42Z", null, 0, 0, "0900006483d7e6be"], ["EPA-HQ-OAR-2002-0095-0231", "EPA", "EPA-HQ-OAR-2002-0095", "Memorandum to William Schrock, USEPA/OAQPS/ESD/OCG, from Thomas Holloway, Midwest Research Institute (MRI) regarding Major and Area Sources in the Cellulose Products Manufacturing Industry EPA Contract No. 68-D6-0012; Task Order No. 0041; ESD No. 97/06 MRI Project No. 4803-41. [A-93-39-II-B-33]", "Supporting & Related Material", "Memorandum", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:45:49Z", null, 0, 0, "0900006483d7e6c0"], ["EPA-HQ-OAR-2002-0095-0233", "EPA", "EPA-HQ-OAR-2002-0095", "Memorandum to William Schrock, USEPA/OAQPS/ESD/OCG, from Karen Schmidtke et al., Midwest Research Institute (MRI) regarding Industry Profile of Cellulose Products Manufacturing Facilities in the U.S. EPA Contract No. 68-D6-0012; Task Order No. 0041; ESD No. 97/06 MRI Project No. 4803-41 [A-93-39-II-B-36]", "Supporting & Related Material", "Memorandum", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:45:54Z", null, 0, 0, "0900006483d7e6c2"], ["EPA-HQ-OAR-2002-0095-0224", "EPA", "EPA-HQ-OAR-2002-0095", "TEAP Handbook on Essential Use Allowances, Appendix B: Decisions of the Montreal Protocol 2001- Contains the text of Decisions IV/25, XI/15 and XII/2 [A-93-39-XI-A-3]", "Supporting & Related Material", "Guidance", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:44:37Z", null, 0, 0, "0900006483d7e6de"], ["EPA-HQ-OAR-2002-0095-0207", "EPA", "EPA-HQ-OAR-2002-0095", "Protection of Stratospheric Ozone: Allocation of  Essential Use Allowances for Calendar Year 2002; Notice of Proposed Rulemakina [A-93-39-XII-B-1]", "Supporting & Related Material", "Publication - Previous/Related FR Notice", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:40:24Z", null, 0, 0, "0900006483d7e6f1"], ["EPA-HQ-OAR-2002-0095-0219", "EPA", "EPA-HQ-OAR-2002-0095", "D. J. Ivey, President, Environmental Labs & Services, Incorporated, Carrollton, GA [A-93-39-XI-H-4]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:43:54Z", null, 0, 0, "0900006483d7e6e3"], ["EPA-HQ-OAR-2002-0095-0218", "EPA", "EPA-HQ-OAR-2002-0095", "Letter from Kevin Shelburne, Owner, TEG Puerto Rico, Caguas, PR. [A-93-39-XI-H-5]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:42:12Z", null, 0, 0, "0900006483d7e6e4"], ["EPA-HQ-OAR-2002-0095-0215", "EPA", "EPA-HQ-OAR-2002-0095", "Ron Melton, Western Farmers Electric Cooperative (WFEC), Mooreland, OK. [A-93-39-XI-H-8]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:42:00Z", null, 0, 0, "0900006483d7e6e7"], ["EPA-HQ-OAR-2002-0095-0234", "EPA", "EPA-HQ-OAR-2002-0095", "Economic Impact Analysis for the Proposed Miscellaneous Cellulose Manufacturing Industry NESHAP. USEPA, Contract/Grant No. 68-D-99-024, EPA-452-D-00-00-002, May 2000. [A-93-39-II-B-45]", "Supporting & Related Material", "Publication - USEPA", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:45:56Z", null, 0, 0, "0900006483d7e6c3"], ["EPA-HQ-OAR-2002-0095-0222", "EPA", "EPA-HQ-OAR-2002-0095", "T.U. Powell, Lab Director, EcoTest Laboratories, Incorporated, North Babylon, NY [A-93-39-XI-H-1]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:44:03Z", null, 0, 0, "0900006483d7e6e0"], ["EPA-HQ-OAR-2002-0095-0213", "EPA", "EPA-HQ-OAR-2002-0095", "Letter to . Lester M. Crawford, Jr, FDA from Brian McLean, EPA requesting  determination on the amount of chlorofluorocarbons (CFCs) for metered-dose inhalers (MDIs) in the year 2003. [A-93-39-XII-A-1]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:41:40Z", null, 0, 0, "0900006483d7e6ea"], ["EPA-HQ-OAR-2002-0095-0236", "EPA", "EPA-HQ-OAR-2002-0095", "Letter to Paul Stolpman, USEPA, Office of Atmospheric Programs, from Jane Henney, M.D., Commissioner, U.S. Food and Drug Administration (FDA), regarding FDA determination on the amounts of chloroflurocarbons (CFCs) necessary for use in medical devices. [A-93-39-VIII-B-4]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:46:06Z", null, 0, 0, "0900006483d7e6da"], ["EPA-HQ-OAR-2002-0095-0225", "EPA", "EPA-HQ-OAR-2002-0095", "Adams Laboratories, Inc. Renewal of the December 27, 1994 Application Seeking an Essential Use Exemption from the Montreal Protocol's CFC Production and Import Phase-Out for 1997. [A-93-39-II-A-2]", "Supporting & Related Material", "Report", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:45:09Z", null, 0, 0, "0900006483d7e6ba"], ["EPA-HQ-OAR-2002-0095-0217", "EPA", "EPA-HQ-OAR-2002-0095", "Letter from Chuck Wallgren, President, Pollution Control Services, San Antonio, TX. [A-93-39-XI-H-6]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:42:09Z", null, 0, 0, "0900006483d7e6e5"], ["EPA-HQ-OAR-2002-0095-0232", "EPA", "EPA-HQ-OAR-2002-0095", "Memorandum to William Schrock, USEPA/OAQPS/ESD/OCG, from Karen Schmidtke, Midwest Research Institute (MRI) regarding List of Correspondence with Facilities in the Cellulose Products Manufacturing Industry EPA Contract No. 68-D6-0012; Task Order No. 0041; ESD No. 97/06 MRI Project No. 4803-41 [A-93-39-II-B-34]", "Supporting & Related Material", "Memorandum", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:45:51Z", null, 0, 0, "0900006483d7e6c1"], ["EPA-HQ-OAR-2002-0095-0228", "EPA", "EPA-HQ-OAR-2002-0095", "T. C. Coyne, M.D., Vice President, Clinical & Medical Affairs, Medeva Americas, Inc., Fort Worth, TX. [A-93-39-II-A-5]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:45:27Z", null, 0, 0, "0900006483d7e6bd"], ["EPA-HQ-OAR-2002-0095-0220", "EPA", "EPA-HQ-OAR-2002-0095", "N.B. Dellavalle, President, Dellavalle Laboratory, Incorporated, Fresno, CA [A-93-39-XI-H-3]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:43:59Z", null, 0, 0, "0900006483d7e6e2"], ["EPA-HQ-OAR-2002-0095-0209", "EPA", "EPA-HQ-OAR-2002-0095", "Record of EPA meeting with GlaxoSmith Kline. [A-93-39-XII-A-5]", "Supporting & Related Material", "Meeting Materials", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:40:43Z", null, 0, 0, "0900006483d7e6ef"], ["EPA-HQ-OAR-2002-0095-0223", "EPA", "EPA-HQ-OAR-2002-0095", "Protection of Stratospheric Ozone: Allocation of Essential Use Allowances for Calendar Year 2002; and Extension of the De Minimus Exemption for Essential Laboratory and Analytical Uses through Calendar Year 2005; Notice of Proposed Rulemaking 66 FR 55145.[A-93-39-XI-A-4]", "Supporting & Related Material", "Publication - Previous/Related FR Notice", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:44:08Z", null, 0, 0, "0900006483d7e6df"], ["EPA-HQ-OAR-2002-0095-0212", "EPA", "EPA-HQ-OAR-2002-0095", "Letter to Brian McLean, EPA from Lester Crawford, FDA with recommendations on the total amounts of CFC necessary to ensure public health. [A-93-39-XII-A-2]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:41:33Z", null, 0, 0, "0900006483d7e6eb"], ["EPA-HQ-OAR-2002-0095-0210", "EPA", "EPA-HQ-OAR-2002-0095", "Letters to Manufacturers from EPA requesting cooperation in determining the amount of\nchlorofluorocarbons (CFCs) needed to manufacture metered dose inhalers (MDIs) in the US in the year 2003 [A-93-39-XII-A-4]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:41:05Z", null, 0, 0, "0900006483d7e6ee"], ["EPA-HQ-OAR-2002-0095-0229", "EPA", "EPA-HQ-OAR-2002-0095", "J. J. Sciarra, Ph.D., President and Director of Research and Development,\nSciarra Laboratories, Hicksville, NY [A-93-39-II-A-7]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:45:41Z", null, 0, 0, "0900006483d7e6bf"], ["EPA-HQ-OAR-2002-0095-0226", "EPA", "EPA-HQ-OAR-2002-0095", "J. F. Doerner, Director Operations, Dura Pharmaceuticals, San Diego, CA. Nomination for Essential Use Exemption. [A-93-39-II-A-3]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:45:15Z", null, 0, 0, "0900006483d7e6bb"], ["EPA-HQ-OAR-2002-0095-0237", "EPA", "EPA-HQ-OAR-2002-0095", "P. Stolpman, Director, Office of Atmospheric Programs (OAP), Office of Air & Radiation (OAR), USEPA to Dr. B.A. Schwertz, Lead Deputy\nCommissioner, U.S. Food and Drug Administration (FDA). [A-93-39-XI-A-1]", "Supporting & Related Material", "Letter", "2022-07-21T04:00:00Z", 2022, 7, null, null, "2022-07-21T15:46:45Z", null, 0, 0, "0900006483d7e6dc"], ["EPA-HQ-OAR-2002-0095-0042", "EPA", "EPA-HQ-OAR-2002-0095", "Nomination request for essential uses of halons - 1993 \n[A-93-39-I-1]", "Notice", null, "2022-07-13T04:00:00Z", 2022, 7, "2022-07-13T04:00:00Z", null, "2022-07-13T17:52:45Z", "93-2384", 0, 0, "0900006483d7eb6a"], ["EPA-HQ-OAR-2002-0095-0027", "EPA", "EPA-HQ-OAR-2002-0095", "C. J. Sciarra, Vice-President, SCIARRA Laboratories, Inc., Hicksville, NY [A-93-39-IX-A-2]", "Supporting & Related Material", "Letter", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:45:26Z", null, 0, 0, "0900006483d7e6c6"], ["EPA-HQ-OAR-2002-0095-0035", "EPA", "EPA-HQ-OAR-2002-0095", "Minutes of the Meeting with the Food & Drug Administration, Environmental Protection Agency, & 3M Pharmaceuticals on 03-02-00 [A-93-39-VII-E-1]", "Supporting & Related Material", "Memorandum", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:46:52Z", null, 0, 0, "0900006483d7e6cc"], ["EPA-HQ-OAR-2002-0095-0024", "EPA", "EPA-HQ-OAR-2002-0095", "U. S. nomination withdrawal letter[A-93-39-I-3]", "Supporting & Related Material", "Letter", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:45:11Z", null, 0, 0, "0900006483d7eb6c"], ["EPA-HQ-OAR-2002-0095-0036", "EPA", "EPA-HQ-OAR-2002-0095", "C. Dabruzzi, National Account Manager, 3M Pharmaceuticals/ 3MDrug Delivery Systems, Minnesota Mining & Manufacturing Company (3M) [A-93-39-IX-A-8]", "Supporting & Related Material", "Report", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:46:57Z", null, 0, 0, "0900006483d7e6cb"], ["EPA-HQ-OAR-2002-0095-0034", "EPA", "EPA-HQ-OAR-2002-0095", "Minutes of the Teleconference with the Food & Drug Administration, Environmental Protection Agency, & Glaxo Wellcome Pharmaceuticals on\n04-20-00 [A-93-39-VII-E-2]", "Supporting & Related Material", "Memorandum", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:46:49Z", null, 0, 0, "0900006483d7e6cd"], ["EPA-HQ-OAR-2002-0095-0031", "EPA", "EPA-HQ-OAR-2002-0095", "J. E. Henney, M. D., Commissioner, Department of Health & Human Services, Food & Drug Administration, requesting supplemental of their letter on 12-23-99 [A-93-39-VII-H-4]", "Supporting & Related Material", "Letter", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:46:33Z", null, 0, 0, "0900006483d7e6d3"], ["EPA-HQ-OAR-2002-0095-0020", "EPA", "EPA-HQ-OAR-2002-0095", "Letters requesting information under section 114 of the Clean Air Act from essential use applicants for CFCs [A-93-39-VIII-B-2]", "Supporting & Related Material", "Letter", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:08:21Z", null, 0, 0, "0900006483d7e6d8"], ["EPA-HQ-OAR-2002-0095-0041", "EPA", "EPA-HQ-OAR-2002-0095", "J. E. Henney, M.D., Commissioner, Department of Health & Human Services, Food & Drug Administration, requesting supplemental of their letter on 01-21-00 [A-93-39-VII-H-5]", "Supporting & Related Material", "Letter", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:47:44Z", null, 0, 0, "0900006483d7e6d4"], ["EPA-HQ-OAR-2002-0095-0023", "EPA", "EPA-HQ-OAR-2002-0095", "U. S. nomination letter for essential uses of halons - 1993 \n[A-93-39-I-2]", "Supporting & Related Material", "Letter", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:45:06Z", null, 0, 0, "0900006483d7eb6b"], ["EPA-HQ-OAR-2002-0095-0029", "EPA", "EPA-HQ-OAR-2002-0095", "J. A. Nusser, Senior Director, Environmental Compliance and Projects, Schering -Plough Corporation, Kenilworth, NJ [A-93-39-IX-A-5]", "Supporting & Related Material", "Publication - Copyrighted Materials", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:46:01Z", null, 0, 0, "0900006483d7e6c8"], ["EPA-HQ-OAR-2002-0095-0038", "EPA", "EPA-HQ-OAR-2002-0095", "J. A. Nusser, Senior Director, Environmental Compliance and Projects, Schering-Plough Corporation, Kenilworth, NJ [A-93-39-IX-A-6]", "Supporting & Related Material", "Letter", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:47:05Z", null, 0, 0, "0900006483d7e6c9"], ["EPA-HQ-OAR-2002-0095-0033", "EPA", "EPA-HQ-OAR-2002-0095", "Minutes of the Teleconference with the Food & Drug Administration, Environmental Protection Agency, & Medisol Pharmaceuticals on 05-22-00 [A-93-39-VII-E-3]", "Supporting & Related Material", "Memorandum", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:46:47Z", null, 0, 0, "0900006483d7e6ce"], ["EPA-HQ-OAR-2002-0095-0037", "EPA", "EPA-HQ-OAR-2002-0095", "J. F. Devaney, Aventis Pharma, Washington, D. C. [A-93-39-IX-A-7]", "Supporting & Related Material", "Letter", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:47:01Z", null, 0, 0, "0900006483d7e6ca"], ["EPA-HQ-OAR-2002-0095-0026", "EPA", "EPA-HQ-OAR-2002-0095", "S. D. Taylor, Assistant Director, Environment, BP Exploration (Alaska) Inc.; J. Hegna, Director, Regulatory Affairs, Phillips Alaska, Inc.; W. Jim Sweeney, Corp. Environmental Director, CHQ Support Services, Alyeska Pipeline Service Company, Anchorage, AK [A-93-39-IX-A-1]", "Supporting & Related Material", "Letter", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:45:23Z", null, 0, 0, "0900006483d7e6c5"], ["EPA-HQ-OAR-2002-0095-0032", "EPA", "EPA-HQ-OAR-2002-0095", "D. Hufford, Director, Strataspheric Protection Division, USEPA, responding to comments submitted by 3M Drug Delivery Systems (see VII-D- 01) [A-93-39-VII-H-1]", "Supporting & Related Material", "Letter", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:46:44Z", null, 0, 0, "0900006483d7e6cf"], ["EPA-HQ-OAR-2002-0095-0022", "EPA", "EPA-HQ-OAR-2002-0095", "J. E. Henney, M.D., Commissioner, Department of Health & Human Services, Food & Drug Administration, to supplement 03-06-00 letter [A-93-39-VII-H-7]", "Supporting & Related Material", "Letter", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:09:04Z", null, 0, 0, "0900006483d7e6d6"], ["EPA-HQ-OAR-2002-0095-0021", "EPA", "EPA-HQ-OAR-2002-0095", "Decision XI/14 from the Report on the Eleventh Meeting of the Parties, to the Montreal Protocol [A-93-39-VIII-B-1]", "Supporting & Related Material", "Report", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:09:02Z", null, 0, 0, "0900006483d7e6d7"], ["EPA-HQ-OAR-2002-0095-0040", "EPA", "EPA-HQ-OAR-2002-0095", "D. Hufford, Director, Stratospheric Protection Division, USEPA, requesting\nassistance from the Food & Drug Administration [A-93-39-VII-H-3]", "Supporting & Related Material", "Letter", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:47:36Z", null, 0, 0, "0900006483d7e6d1"], ["EPA-HQ-OAR-2002-0095-0030", "EPA", "EPA-HQ-OAR-2002-0095", "J. E. Henney, M.D., Commissioner, Department of Health & Human Services, Food & Drug Administration, to supplement 05-05-00 letter [A-93-39-VII-H-6]", "Supporting & Related Material", "Letter", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:46:17Z", null, 0, 0, "0900006483d7e6d5"], ["EPA-HQ-OAR-2002-0095-0025", "EPA", "EPA-HQ-OAR-2002-0095", "C. J. Morris and M. D. Woolf, Piper & Marbury L.L.P., Washington, DC on behalf of Aeropharm Technology, Inc., Edison, NJ. Application of Aeropharm Technology, Inc. For an Essential Use Exemption to the Phase-Out of Ozone-Depleting Substances.  [A-93-39-II-A-1]", "Supporting & Related Material", "Report", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:45:16Z", null, 0, 0, "0900006483d7eb6d"], ["EPA-HQ-OAR-2002-0095-0019", "EPA", "EPA-HQ-OAR-2002-0095", "Letter from Paul Stolpman, Director, Office of Atmospheric Programs, EPA to essential Letter to Janet Woodcock M. D., Director of the Center for Drug Evaluation and Research, FDA requesting consultation on necessary CFCs for 2001 [A-93-39-VIII-B-3]", "Supporting & Related Material", "Letter", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:08:14Z", null, 0, 0, "0900006483d7e6d9"], ["EPA-HQ-OAR-2002-0095-0028", "EPA", "EPA-HQ-OAR-2002-0095", "P. Blenkinsop, IPAC Secretariat, International Pharmaceutical Aerosol Consortium (IPAC), Washington, D. C. [A-93-39-IX-A-3]", "Supporting & Related Material", "Letter", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:45:48Z", null, 0, 0, "0900006483d7e6c7"], ["EPA-HQ-OAR-2002-0095-0039", "EPA", "EPA-HQ-OAR-2002-0095", "T. Land, Stratospheric Protection Division, USEPA, responding to comments submitted by General Electric Company (see X-D-05) [A-93-39-VII-H-2]", "Supporting & Related Material", "Letter", "2022-06-30T04:00:00Z", 2022, 6, null, null, "2022-07-01T03:47:30Z", null, 0, 0, "0900006483d7e6d0"]], "truncated": false, "filtered_table_rows_count": 59, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"agency_id\" = :p0 and \"docket_id\" = :p1 and \"posted_year\" = :p2 order by posted_date desc limit 101", "params": {"p0": "EPA", "p1": "EPA-HQ-OAR-2002-0095", "p2": "2022"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=EPA&docket_id=EPA-HQ-OAR-2002-0095&posted_year=2022", "results": [{"value": "EPA", "label": "EPA", "count": 59, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?docket_id=EPA-HQ-OAR-2002-0095&posted_year=2022", "selected": true}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=EPA&docket_id=EPA-HQ-OAR-2002-0095&posted_year=2022", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 55, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=EPA&docket_id=EPA-HQ-OAR-2002-0095&posted_year=2022&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Rule", "label": "Rule", "count": 2, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=EPA&docket_id=EPA-HQ-OAR-2002-0095&posted_year=2022&document_type=Rule", "selected": false}, {"value": "Notice", "label": "Notice", "count": 1, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=EPA&docket_id=EPA-HQ-OAR-2002-0095&posted_year=2022&document_type=Notice", "selected": false}, {"value": "Proposed Rule", "label": "Proposed Rule", "count": 1, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=EPA&docket_id=EPA-HQ-OAR-2002-0095&posted_year=2022&document_type=Proposed+Rule", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=EPA&docket_id=EPA-HQ-OAR-2002-0095&posted_year=2022", "results": [{"value": 2022, "label": 2022, "count": 59, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=EPA&docket_id=EPA-HQ-OAR-2002-0095", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=EPA&docket_id=EPA-HQ-OAR-2002-0095&posted_year=2022&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=EPA&docket_id=EPA-HQ-OAR-2002-0095&posted_year=2022&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=EPA&docket_id=EPA-HQ-OAR-2002-0095&posted_year=2022&_facet=posted_month"}, {"name": "comment_start_date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=EPA&docket_id=EPA-HQ-OAR-2002-0095&posted_year=2022&_facet=comment_start_date"}, {"name": "posted_date", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=EPA&docket_id=EPA-HQ-OAR-2002-0095&posted_year=2022&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=EPA&docket_id=EPA-HQ-OAR-2002-0095&posted_year=2022&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=EPA&docket_id=EPA-HQ-OAR-2002-0095&posted_year=2022&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=EPA&docket_id=EPA-HQ-OAR-2002-0095&posted_year=2022&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 2005.5327919544652, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}